NO326508B1 - Krystaller som inneholder et eplesyresalt av N-[2-(dietylamino)etyl]-5-[(5-fluor- 2-okso-3H-indol-3-yliden)metyl]-2,4-dimetyl-1H-pyrrol-3-karboksamid, fremgangsmater for fremstilling av disse og preparater derav - Google Patents

Krystaller som inneholder et eplesyresalt av N-[2-(dietylamino)etyl]-5-[(5-fluor- 2-okso-3H-indol-3-yliden)metyl]-2,4-dimetyl-1H-pyrrol-3-karboksamid, fremgangsmater for fremstilling av disse og preparater derav Download PDF

Info

Publication number: NO326508B1
Authority: NO; Norway
Prior art keywords: crystal; malic acid; theta; ray diffraction; degrees
Prior art date: 2001-08-15

Application number

NO20041054A

Other languages

English (en)

Norwegian (no)

Other versions

NO20041054L (no

Inventor

Thomas J Fleck

Michael Hawley

Stephen P Prescott

Mark T Maloney

Original Assignee

Pharmacia & Upjohn Co Llc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-08-15

Filing date

2004-03-12

Publication date

2008-12-15

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23211067&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO326508(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2004-03-12 Application filed by Pharmacia & Upjohn Co Llc filed Critical Pharmacia & Upjohn Co Llc

2004-03-12 Publication of NO20041054L publication Critical patent/NO20041054L/no

2008-12-15 Publication of NO326508B1 publication Critical patent/NO326508B1/no

Links

239000013078 crystal Substances 0.000 title claims description 189
238000000034 method Methods 0.000 title claims description 40
WINHZLLDWRZWRT-UHFFFAOYSA-N N-[2-(diethylamino)ethyl]-5-[(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide Chemical compound CCN(CC)CCNC(=O)C1=C(C)NC(C=C2C3=CC(F)=CC=C3NC2=O)=C1C WINHZLLDWRZWRT-UHFFFAOYSA-N 0.000 title claims description 34
150000004701 malic acid derivatives Chemical class 0.000 title claims description 29
238000002360 preparation method Methods 0.000 title claims description 29
239000000203 mixture Substances 0.000 claims description 35
BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 claims description 34
238000000634 powder X-ray diffraction Methods 0.000 claims description 33
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 27
239000002904 solvent Substances 0.000 claims description 27
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 24
238000002425 crystallisation Methods 0.000 claims description 21
230000008025 crystallization Effects 0.000 claims description 21
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 21
-1 5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene Chemical group 0.000 claims description 19
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 18
150000003839 salts Chemical class 0.000 claims description 17
BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 claims description 16
235000011090 malic acid Nutrition 0.000 claims description 15
239000011549 crystallization solution Substances 0.000 claims description 13
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 12
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 12
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 10
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 9
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 9
YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims description 9
238000002441 X-ray diffraction Methods 0.000 claims description 9
LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 claims description 8
238000001816 cooling Methods 0.000 claims description 8
229940116298 l- malic acid Drugs 0.000 claims description 7
229940099690 malic acid Drugs 0.000 claims description 7
239000001630 malic acid Substances 0.000 claims description 7
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 6
230000015572 biosynthetic process Effects 0.000 claims description 5
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 5
150000001875 compounds Chemical class 0.000 claims description 4
238000004519 manufacturing process Methods 0.000 claims description 4
238000003756 stirring Methods 0.000 claims description 4
230000001939 inductive effect Effects 0.000 claims description 3
238000010438 heat treatment Methods 0.000 claims description 2
239000000825 pharmaceutical preparation Substances 0.000 description 40
239000000126 substance Substances 0.000 description 19
239000000463 material Substances 0.000 description 15
239000000243 solution Substances 0.000 description 13
239000003814 drug Substances 0.000 description 11
238000009472 formulation Methods 0.000 description 11
239000007787 solid Substances 0.000 description 11
238000001179 sorption measurement Methods 0.000 description 10
239000012458 free base Substances 0.000 description 8
239000002775 capsule Substances 0.000 description 7
239000000969 carrier Substances 0.000 description 7
238000000113 differential scanning calorimetry Methods 0.000 description 7
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
230000000694 effects Effects 0.000 description 7
239000000546 pharmaceutical excipient Substances 0.000 description 7
229940079593 drug Drugs 0.000 description 6
239000000523 sample Substances 0.000 description 6
239000000725 suspension Substances 0.000 description 6
108010010803 Gelatin Proteins 0.000 description 5
206010028980 Neoplasm Diseases 0.000 description 5
239000004480 active ingredient Substances 0.000 description 5
239000002246 antineoplastic agent Substances 0.000 description 5
229940127089 cytotoxic agent Drugs 0.000 description 5
239000008273 gelatin Substances 0.000 description 5
229920000159 gelatin Polymers 0.000 description 5
235000019322 gelatine Nutrition 0.000 description 5
235000011852 gelatine desserts Nutrition 0.000 description 5
239000007924 injection Substances 0.000 description 5
238000002347 injection Methods 0.000 description 5
239000000155 melt Substances 0.000 description 5
238000002844 melting Methods 0.000 description 5
230000008018 melting Effects 0.000 description 5
239000002245 particle Substances 0.000 description 5
206010006187 Breast cancer Diseases 0.000 description 4
208000026310 Breast neoplasm Diseases 0.000 description 4
229920002472 Starch Polymers 0.000 description 4
238000004113 cell culture Methods 0.000 description 4
239000003795 chemical substances by application Substances 0.000 description 4
208000035475 disorder Diseases 0.000 description 4
238000004090 dissolution Methods 0.000 description 4
239000007788 liquid Substances 0.000 description 4
230000036470 plasma concentration Effects 0.000 description 4
239000001267 polyvinylpyrrolidone Substances 0.000 description 4
229920000036 polyvinylpyrrolidone Polymers 0.000 description 4
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 4
239000000843 powder Substances 0.000 description 4
238000012545 processing Methods 0.000 description 4
102000004169 proteins and genes Human genes 0.000 description 4
108090000623 proteins and genes Proteins 0.000 description 4
239000007790 solid phase Substances 0.000 description 4
239000003381 stabilizer Substances 0.000 description 4
238000013268 sustained release Methods 0.000 description 4
239000012730 sustained-release form Substances 0.000 description 4
238000002411 thermogravimetry Methods 0.000 description 4
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 3
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
102000009465 Growth Factor Receptors Human genes 0.000 description 3
108010009202 Growth Factor Receptors Proteins 0.000 description 3
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
230000015556 catabolic process Effects 0.000 description 3
238000006731 degradation reaction Methods 0.000 description 3
201000010099 disease Diseases 0.000 description 3
239000002552 dosage form Substances 0.000 description 3
239000008298 dragée Substances 0.000 description 3
230000004927 fusion Effects 0.000 description 3
239000000499 gel Substances 0.000 description 3
238000000892 gravimetry Methods 0.000 description 3
238000000227 grinding Methods 0.000 description 3
239000008101 lactose Substances 0.000 description 3
239000002502 liposome Substances 0.000 description 3
230000000704 physical effect Effects 0.000 description 3
229920001223 polyethylene glycol Polymers 0.000 description 3
239000000600 sorbitol Substances 0.000 description 3
235000019698 starch Nutrition 0.000 description 3
235000000346 sugar Nutrition 0.000 description 3
239000003826 tablet Substances 0.000 description 3
AKWIAIDKXNKXDI-UHFFFAOYSA-N 1h-pyrrole-3-carboxamide Chemical compound NC(=O)C=1C=CNC=1 AKWIAIDKXNKXDI-UHFFFAOYSA-N 0.000 description 2
208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 2
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
208000010833 Chronic myeloid leukaemia Diseases 0.000 description 2
AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 2
208000017604 Hodgkin disease Diseases 0.000 description 2
208000010747 Hodgkins lymphoma Diseases 0.000 description 2
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
241001465754 Metazoa Species 0.000 description 2
208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 2
206010033128 Ovarian cancer Diseases 0.000 description 2
206010061535 Ovarian neoplasm Diseases 0.000 description 2
NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
108091000080 Phosphotransferase Proteins 0.000 description 2
102000009516 Protein Serine-Threonine Kinases Human genes 0.000 description 2
108010009341 Protein Serine-Threonine Kinases Proteins 0.000 description 2
108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 2
102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 2
NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 2
208000024313 Testicular Neoplasms Diseases 0.000 description 2
206010057644 Testis cancer Diseases 0.000 description 2
GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 description 2
239000000654 additive Substances 0.000 description 2
239000000443 aerosol Substances 0.000 description 2
238000004458 analytical method Methods 0.000 description 2
238000010171 animal model Methods 0.000 description 2
239000007864 aqueous solution Substances 0.000 description 2
238000003556 assay Methods 0.000 description 2
239000000872 buffer Substances 0.000 description 2
239000001768 carboxy methyl cellulose Substances 0.000 description 2
210000004027 cell Anatomy 0.000 description 2
230000024245 cell differentiation Effects 0.000 description 2
230000032823 cell division Effects 0.000 description 2
230000010261 cell growth Effects 0.000 description 2
239000001913 cellulose Substances 0.000 description 2
229920002678 cellulose Polymers 0.000 description 2
235000010980 cellulose Nutrition 0.000 description 2
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Natural products OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 2
230000007547 defect Effects 0.000 description 2
239000003937 drug carrier Substances 0.000 description 2
238000012377 drug delivery Methods 0.000 description 2
239000000839 emulsion Substances 0.000 description 2
239000010685 fatty oil Substances 0.000 description 2
239000000945 filler Substances 0.000 description 2
238000001914 filtration Methods 0.000 description 2
229960002949 fluorouracil Drugs 0.000 description 2
238000004128 high performance liquid chromatography Methods 0.000 description 2
239000012535 impurity Substances 0.000 description 2
JYGFTBXVXVMTGB-UHFFFAOYSA-N indolin-2-one Chemical class C1=CC=C2NC(=O)CC2=C1 JYGFTBXVXVMTGB-UHFFFAOYSA-N 0.000 description 2
230000005764 inhibitory process Effects 0.000 description 2
208000032839 leukemia Diseases 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
239000003921 oil Substances 0.000 description 2
235000019198 oils Nutrition 0.000 description 2
239000008183 oral pharmaceutical preparation Substances 0.000 description 2
150000002894 organic compounds Chemical class 0.000 description 2
238000012856 packing Methods 0.000 description 2
238000007911 parenteral administration Methods 0.000 description 2
230000000144 pharmacologic effect Effects 0.000 description 2
230000026731 phosphorylation Effects 0.000 description 2
238000006366 phosphorylation reaction Methods 0.000 description 2
102000020233 phosphotransferase Human genes 0.000 description 2
239000004033 plastic Substances 0.000 description 2
229920003023 plastic Polymers 0.000 description 2
BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
238000001144 powder X-ray diffraction data Methods 0.000 description 2
235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
230000000087 stabilizing effect Effects 0.000 description 2
239000008107 starch Substances 0.000 description 2
150000008163 sugars Chemical class 0.000 description 2
239000000454 talc Substances 0.000 description 2
229910052623 talc Inorganic materials 0.000 description 2
235000012222 talc Nutrition 0.000 description 2
201000003120 testicular cancer Diseases 0.000 description 2
229940124597 therapeutic agent Drugs 0.000 description 2
WYWHKKSPHMUBEB-UHFFFAOYSA-N tioguanine Chemical compound N1C(N)=NC(=S)C2=C1N=CN2 WYWHKKSPHMUBEB-UHFFFAOYSA-N 0.000 description 2
JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
230000001988 toxicity Effects 0.000 description 2
231100000419 toxicity Toxicity 0.000 description 2
230000007704 transition Effects 0.000 description 2
230000004580 weight loss Effects 0.000 description 2
MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
FDKXTQMXEQVLRF-ZHACJKMWSA-N (E)-dacarbazine Chemical compound CN(C)\N=N\c1[nH]cnc1C(N)=O FDKXTQMXEQVLRF-ZHACJKMWSA-N 0.000 description 1
BJEPYKJPYRNKOW-UWTATZPHSA-N (R)-malic acid Chemical compound OC(=O)[C@H](O)CC(O)=O BJEPYKJPYRNKOW-UWTATZPHSA-N 0.000 description 1
DDMOUSALMHHKOS-UHFFFAOYSA-N 1,2-dichloro-1,1,2,2-tetrafluoroethane Chemical compound FC(F)(Cl)C(F)(F)Cl DDMOUSALMHHKOS-UHFFFAOYSA-N 0.000 description 1
102100025573 1-alkyl-2-acetylglycerophosphocholine esterase Human genes 0.000 description 1
IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
CTRPRMNBTVRDFH-UHFFFAOYSA-N 2-n-methyl-1,3,5-triazine-2,4,6-triamine Chemical class CNC1=NC(N)=NC(N)=N1 CTRPRMNBTVRDFH-UHFFFAOYSA-N 0.000 description 1
NDMPLJNOPCLANR-UHFFFAOYSA-N 3,4-dihydroxy-15-(4-hydroxy-18-methoxycarbonyl-5,18-seco-ibogamin-18-yl)-16-methoxy-1-methyl-6,7-didehydro-aspidospermidine-3-carboxylic acid methyl ester Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 NDMPLJNOPCLANR-UHFFFAOYSA-N 0.000 description 1
FEBBTRXSBLXZRV-UHFFFAOYSA-N 3-hydroxy-1-[4-(3-hydroxypropanoyl)piperazin-1-yl]propan-1-one Chemical compound OCCC(=O)N1CCN(C(=O)CCO)CC1 FEBBTRXSBLXZRV-UHFFFAOYSA-N 0.000 description 1
AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 description 1
QISOBCMNUJQOJU-UHFFFAOYSA-N 4-bromo-1h-pyrazole-5-carboxylic acid Chemical compound OC(=O)C=1NN=CC=1Br QISOBCMNUJQOJU-UHFFFAOYSA-N 0.000 description 1
IDPUKCWIGUEADI-UHFFFAOYSA-N 5-[bis(2-chloroethyl)amino]uracil Chemical compound ClCCN(CCCl)C1=CNC(=O)NC1=O IDPUKCWIGUEADI-UHFFFAOYSA-N 0.000 description 1
PXRKCOCTEMYUEG-UHFFFAOYSA-N 5-aminoisoindole-1,3-dione Chemical compound NC1=CC=C2C(=O)NC(=O)C2=C1 PXRKCOCTEMYUEG-UHFFFAOYSA-N 0.000 description 1
DDIIYGHHUMKDGI-UHFFFAOYSA-N 5-fluoro-1,3-dihydroindol-2-one Chemical compound FC1=CC=C2NC(=O)CC2=C1 DDIIYGHHUMKDGI-UHFFFAOYSA-N 0.000 description 1
FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
VVIAGPKUTFNRDU-UHFFFAOYSA-N 6S-folinic acid Natural products C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-UHFFFAOYSA-N 0.000 description 1
STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 1
244000215068 Acacia senegal Species 0.000 description 1
208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 1
208000031261 Acute myeloid leukaemia Diseases 0.000 description 1
229920001817 Agar Polymers 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 1
108010024976 Asparaginase Proteins 0.000 description 1
208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 1
206010005003 Bladder cancer Diseases 0.000 description 1
108010006654 Bleomycin Proteins 0.000 description 1
208000003174 Brain Neoplasms Diseases 0.000 description 1
COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
GAGWJHPBXLXJQN-UHFFFAOYSA-N Capecitabine Natural products C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1C1C(O)C(O)C(C)O1 GAGWJHPBXLXJQN-UHFFFAOYSA-N 0.000 description 1
GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 description 1
SHHKQEUPHAENFK-UHFFFAOYSA-N Carboquone Chemical compound O=C1C(C)=C(N2CC2)C(=O)C(C(COC(N)=O)OC)=C1N1CC1 SHHKQEUPHAENFK-UHFFFAOYSA-N 0.000 description 1
206010008342 Cervix carcinoma Diseases 0.000 description 1
JWBOIMRXGHLCPP-UHFFFAOYSA-N Chloditan Chemical compound C=1C=CC=C(Cl)C=1C(C(Cl)Cl)C1=CC=C(Cl)C=C1 JWBOIMRXGHLCPP-UHFFFAOYSA-N 0.000 description 1
208000006332 Choriocarcinoma Diseases 0.000 description 1
206010009944 Colon cancer Diseases 0.000 description 1
RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
229920002261 Corn starch Polymers 0.000 description 1
CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 1
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
108010092160 Dactinomycin Proteins 0.000 description 1
229920002307 Dextran Polymers 0.000 description 1
239000004338 Dichlorodifluoromethane Substances 0.000 description 1
LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
241000792859 Enema Species 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
HTIJFSOGRVMCQR-UHFFFAOYSA-N Epirubicin Natural products COc1cccc2C(=O)c3c(O)c4CC(O)(CC(OC5CC(N)C(=O)C(C)O5)c4c(O)c3C(=O)c12)C(=O)CO HTIJFSOGRVMCQR-UHFFFAOYSA-N 0.000 description 1
208000032027 Essential Thrombocythemia Diseases 0.000 description 1
206010016654 Fibrosis Diseases 0.000 description 1
206010017533 Fungal infection Diseases 0.000 description 1
229920000084 Gum arabic Polymers 0.000 description 1
238000010268 HPLC based assay Methods 0.000 description 1
239000012981 Hank's balanced salt solution Substances 0.000 description 1
DOMWKUIIPQCAJU-LJHIYBGHSA-N Hydroxyprogesterone caproate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)CCCCC)[C@@]1(C)CC2 DOMWKUIIPQCAJU-LJHIYBGHSA-N 0.000 description 1
208000007766 Kaposi sarcoma Diseases 0.000 description 1
238000003109 Karl Fischer titration Methods 0.000 description 1
FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
206010058467 Lung neoplasm malignant Diseases 0.000 description 1
208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 1
229930195725 Mannitol Natural products 0.000 description 1
102000018697 Membrane Proteins Human genes 0.000 description 1
108010052285 Membrane Proteins Proteins 0.000 description 1
229930192392 Mitomycin Natural products 0.000 description 1
208000034578 Multiple myelomas Diseases 0.000 description 1
NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 1
206010029260 Neuroblastoma Diseases 0.000 description 1
206010030155 Oesophageal carcinoma Diseases 0.000 description 1
229930012538 Paclitaxel Natural products 0.000 description 1
206010061902 Pancreatic neoplasm Diseases 0.000 description 1
206010035226 Plasma cell myeloma Diseases 0.000 description 1
239000002202 Polyethylene glycol Substances 0.000 description 1
208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 1
HFVNWDWLWUCIHC-GUPDPFMOSA-N Prednimustine Chemical compound O=C([C@@]1(O)CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)[C@@H](O)C[C@@]21C)COC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 HFVNWDWLWUCIHC-GUPDPFMOSA-N 0.000 description 1
201000004681 Psoriasis Diseases 0.000 description 1
206010039491 Sarcoma Diseases 0.000 description 1
MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
208000000453 Skin Neoplasms Diseases 0.000 description 1
208000021712 Soft tissue sarcoma Diseases 0.000 description 1
229920002125 Sokalan® Polymers 0.000 description 1
208000005718 Stomach Neoplasms Diseases 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric Acid Chemical compound [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
BPEGJWRSRHCHSN-UHFFFAOYSA-N Temozolomide Chemical compound O=C1N(C)N=NC2=C(C(N)=O)N=CN21 BPEGJWRSRHCHSN-UHFFFAOYSA-N 0.000 description 1
PDMMFKSKQVNJMI-BLQWBTBKSA-N Testosterone propionate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](OC(=O)CC)[C@@]1(C)CC2 PDMMFKSKQVNJMI-BLQWBTBKSA-N 0.000 description 1
FOCVUCIESVLUNU-UHFFFAOYSA-N Thiotepa Chemical compound C1CN1P(N1CC1)(=S)N1CC1 FOCVUCIESVLUNU-UHFFFAOYSA-N 0.000 description 1
229920001615 Tragacanth Polymers 0.000 description 1
FYAMXEPQQLNQDM-UHFFFAOYSA-N Tris(1-aziridinyl)phosphine oxide Chemical compound C1CN1P(N1CC1)(=O)N1CC1 FYAMXEPQQLNQDM-UHFFFAOYSA-N 0.000 description 1
208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
208000006593 Urologic Neoplasms Diseases 0.000 description 1
208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 1
229940122803 Vinca alkaloid Drugs 0.000 description 1
208000033559 Waldenström macroglobulinemia Diseases 0.000 description 1
208000008383 Wilms tumor Diseases 0.000 description 1
USDJGQLNFPZEON-UHFFFAOYSA-N [[4,6-bis(hydroxymethylamino)-1,3,5-triazin-2-yl]amino]methanol Chemical compound OCNC1=NC(NCO)=NC(NCO)=N1 USDJGQLNFPZEON-UHFFFAOYSA-N 0.000 description 1
230000002159 abnormal effect Effects 0.000 description 1
235000010489 acacia gum Nutrition 0.000 description 1
239000000205 acacia gum Substances 0.000 description 1
RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 description 1
230000001154 acute effect Effects 0.000 description 1
239000008272 agar Substances 0.000 description 1
235000010419 agar Nutrition 0.000 description 1
229940072056 alginate Drugs 0.000 description 1
235000010443 alginic acid Nutrition 0.000 description 1
229920000615 alginic acid Polymers 0.000 description 1
229940045714 alkyl sulfonate alkylating agent Drugs 0.000 description 1
150000008052 alkyl sulfonates Chemical class 0.000 description 1
229940100198 alkylating agent Drugs 0.000 description 1
239000002168 alkylating agent Substances 0.000 description 1
229960000473 altretamine Drugs 0.000 description 1
229910052782 aluminium Inorganic materials 0.000 description 1
XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
229960003437 aminoglutethimide Drugs 0.000 description 1
ROBVIMPUHSLWNV-UHFFFAOYSA-N aminoglutethimide Chemical compound C=1C=C(N)C=CC=1C1(CC)CCC(=O)NC1=O ROBVIMPUHSLWNV-UHFFFAOYSA-N 0.000 description 1
229960002932 anastrozole Drugs 0.000 description 1
YBBLVLTVTVSKRW-UHFFFAOYSA-N anastrozole Chemical compound N#CC(C)(C)C1=CC(C(C)(C#N)C)=CC(CN2N=CN=C2)=C1 YBBLVLTVTVSKRW-UHFFFAOYSA-N 0.000 description 1
239000003098 androgen Substances 0.000 description 1
229940030486 androgens Drugs 0.000 description 1
229940046836 anti-estrogen Drugs 0.000 description 1
230000001833 anti-estrogenic effect Effects 0.000 description 1
229940045686 antimetabolites antineoplastic purine analogs Drugs 0.000 description 1
229940045687 antimetabolites folic acid analogs Drugs 0.000 description 1
229940045713 antineoplastic alkylating drug ethylene imines Drugs 0.000 description 1
229940045688 antineoplastic antimetabolites pyrimidine analogues Drugs 0.000 description 1
239000008365 aqueous carrier Substances 0.000 description 1
239000003886 aromatase inhibitor Substances 0.000 description 1
229940046844 aromatase inhibitors Drugs 0.000 description 1
239000011668 ascorbic acid Substances 0.000 description 1
239000000305 astragalus gummifer gum Substances 0.000 description 1
125000004429 atom Chemical group 0.000 description 1
150000001541 aziridines Chemical class 0.000 description 1
230000004888 barrier function Effects 0.000 description 1
239000002585 base Substances 0.000 description 1
229950005567 benzodepa Drugs 0.000 description 1
VFIUCBTYGKMLCM-UHFFFAOYSA-N benzyl n-[bis(aziridin-1-yl)phosphoryl]carbamate Chemical compound C=1C=CC=CC=1COC(=O)NP(=O)(N1CC1)N1CC1 VFIUCBTYGKMLCM-UHFFFAOYSA-N 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
238000004166 bioassay Methods 0.000 description 1
230000003115 biocidal effect Effects 0.000 description 1
229960001561 bleomycin Drugs 0.000 description 1
OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 1
210000000481 breast Anatomy 0.000 description 1
SXDBWCPKPHAZSM-UHFFFAOYSA-N bromic acid Chemical compound OBr(=O)=O SXDBWCPKPHAZSM-UHFFFAOYSA-N 0.000 description 1
229960002092 busulfan Drugs 0.000 description 1
229910000019 calcium carbonate Inorganic materials 0.000 description 1
239000001506 calcium phosphate Substances 0.000 description 1
229910000389 calcium phosphate Inorganic materials 0.000 description 1
235000011010 calcium phosphates Nutrition 0.000 description 1
238000007707 calorimetry Methods 0.000 description 1
229960004117 capecitabine Drugs 0.000 description 1
239000007963 capsule composition Substances 0.000 description 1
239000004202 carbamide Substances 0.000 description 1
229910052799 carbon Inorganic materials 0.000 description 1
239000001569 carbon dioxide Substances 0.000 description 1
229960004424 carbon dioxide Drugs 0.000 description 1
229910002092 carbon dioxide Inorganic materials 0.000 description 1
229960002115 carboquone Drugs 0.000 description 1
210000000170 cell membrane Anatomy 0.000 description 1
230000036755 cellular response Effects 0.000 description 1
201000010881 cervical cancer Diseases 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
229960004630 chlorambucil Drugs 0.000 description 1
JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 description 1
208000032852 chronic lymphocytic leukemia Diseases 0.000 description 1
DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
229960004316 cisplatin Drugs 0.000 description 1
235000015165 citric acid Nutrition 0.000 description 1
229960004106 citric acid Drugs 0.000 description 1
238000000576 coating method Methods 0.000 description 1
229940110456 cocoa butter Drugs 0.000 description 1
235000019868 cocoa butter Nutrition 0.000 description 1
210000001072 colon Anatomy 0.000 description 1
208000029742 colonic neoplasm Diseases 0.000 description 1
238000004320 controlled atmosphere Methods 0.000 description 1
229910052802 copper Inorganic materials 0.000 description 1
239000010949 copper Substances 0.000 description 1
239000008120 corn starch Substances 0.000 description 1
229940099112 cornstarch Drugs 0.000 description 1
WZHCOOQXZCIUNC-UHFFFAOYSA-N cyclandelate Chemical compound C1C(C)(C)CC(C)CC1OC(=O)C(O)C1=CC=CC=C1 WZHCOOQXZCIUNC-UHFFFAOYSA-N 0.000 description 1
HCAJEUSONLESMK-UHFFFAOYSA-N cyclohexylsulfamic acid Chemical compound OS(=O)(=O)NC1CCCCC1 HCAJEUSONLESMK-UHFFFAOYSA-N 0.000 description 1
229960004397 cyclophosphamide Drugs 0.000 description 1
229960000684 cytarabine Drugs 0.000 description 1
230000001086 cytosolic effect Effects 0.000 description 1
229960003901 dacarbazine Drugs 0.000 description 1
229960000640 dactinomycin Drugs 0.000 description 1
238000007405 data analysis Methods 0.000 description 1
238000013480 data collection Methods 0.000 description 1
229960000975 daunorubicin Drugs 0.000 description 1
STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 1
239000003405 delayed action preparation Substances 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
238000013461 design Methods 0.000 description 1
206010012601 diabetes mellitus Diseases 0.000 description 1
PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 description 1
229940042935 dichlorodifluoromethane Drugs 0.000 description 1
235000019404 dichlorodifluoromethane Nutrition 0.000 description 1
229940087091 dichlorotetrafluoroethane Drugs 0.000 description 1
235000014113 dietary fatty acids Nutrition 0.000 description 1
RGLYKWWBQGJZGM-ISLYRVAYSA-N diethylstilbestrol Chemical compound C=1C=C(O)C=CC=1C(/CC)=C(\CC)C1=CC=C(O)C=C1 RGLYKWWBQGJZGM-ISLYRVAYSA-N 0.000 description 1
208000037765 diseases and disorders Diseases 0.000 description 1
235000021186 dishes Nutrition 0.000 description 1
239000002270 dispersing agent Substances 0.000 description 1
229960004679 doxorubicin Drugs 0.000 description 1
238000001035 drying Methods 0.000 description 1
239000000975 dye Substances 0.000 description 1
230000001804 emulsifying effect Effects 0.000 description 1
239000007920 enema Substances 0.000 description 1
229940079360 enema for constipation Drugs 0.000 description 1
230000002255 enzymatic effect Effects 0.000 description 1
229940088598 enzyme Drugs 0.000 description 1
229960001904 epirubicin Drugs 0.000 description 1
229960001842 estramustine Drugs 0.000 description 1
FRPJXPJMRWBBIH-RBRWEJTLSA-N estramustine Chemical compound ClCCN(CCCl)C(=O)OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 FRPJXPJMRWBBIH-RBRWEJTLSA-N 0.000 description 1
229940011871 estrogen Drugs 0.000 description 1
239000000262 estrogen Substances 0.000 description 1
239000000328 estrogen antagonist Substances 0.000 description 1
LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
229940093471 ethyl oleate Drugs 0.000 description 1
VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 1
229960005420 etoposide Drugs 0.000 description 1
238000001704 evaporation Methods 0.000 description 1
230000008020 evaporation Effects 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
239000000194 fatty acid Substances 0.000 description 1
229930195729 fatty acid Natural products 0.000 description 1
230000004761 fibrosis Effects 0.000 description 1
239000011888 foil Substances 0.000 description 1
150000002224 folic acids Chemical class 0.000 description 1
VVIAGPKUTFNRDU-ABLWVSNPSA-N folinic acid Chemical compound C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-ABLWVSNPSA-N 0.000 description 1
235000008191 folinic acid Nutrition 0.000 description 1
239000011672 folinic acid Substances 0.000 description 1
239000001530 fumaric acid Substances 0.000 description 1
208000024386 fungal infectious disease Diseases 0.000 description 1
239000007789 gas Substances 0.000 description 1
206010017758 gastric cancer Diseases 0.000 description 1
229960005277 gemcitabine Drugs 0.000 description 1
SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 1
230000014509 gene expression Effects 0.000 description 1
239000011521 glass Substances 0.000 description 1
208000005017 glioblastoma Diseases 0.000 description 1
125000005456 glyceride group Chemical group 0.000 description 1
239000003102 growth factor Substances 0.000 description 1
125000005843 halogen group Chemical group 0.000 description 1
201000010536 head and neck cancer Diseases 0.000 description 1
208000014829 head and neck neoplasm Diseases 0.000 description 1
UUVWYPNAQBNQJQ-UHFFFAOYSA-N hexamethylmelamine Chemical compound CN(C)C1=NC(N(C)C)=NC(N(C)C)=N1 UUVWYPNAQBNQJQ-UHFFFAOYSA-N 0.000 description 1
229940088597 hormone Drugs 0.000 description 1
239000005556 hormone Substances 0.000 description 1
239000003667 hormone antagonist Substances 0.000 description 1
230000002209 hydrophobic effect Effects 0.000 description 1
229920001600 hydrophobic polymer Polymers 0.000 description 1
125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
229950000801 hydroxyprogesterone caproate Drugs 0.000 description 1
239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
229960001101 ifosfamide Drugs 0.000 description 1
HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 description 1
238000002513 implantation Methods 0.000 description 1
DBIGHPPNXATHOF-UHFFFAOYSA-N improsulfan Chemical compound CS(=O)(=O)OCCCNCCCOS(C)(=O)=O DBIGHPPNXATHOF-UHFFFAOYSA-N 0.000 description 1
229950008097 improsulfan Drugs 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
238000010348 incorporation Methods 0.000 description 1
238000001802 infusion Methods 0.000 description 1
239000003112 inhibitor Substances 0.000 description 1
230000000968 intestinal effect Effects 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
238000010255 intramuscular injection Methods 0.000 description 1
239000007927 intramuscular injection Substances 0.000 description 1
238000007912 intraperitoneal administration Methods 0.000 description 1
238000007913 intrathecal administration Methods 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
238000007914 intraventricular administration Methods 0.000 description 1
238000011835 investigation Methods 0.000 description 1
239000003456 ion exchange resin Substances 0.000 description 1
229920003303 ion-exchange polymer Polymers 0.000 description 1
FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 1
238000002372 labelling Methods 0.000 description 1
229960001691 leucovorin Drugs 0.000 description 1
239000003446 ligand Substances 0.000 description 1
229940057995 liquid paraffin Drugs 0.000 description 1
239000007937 lozenge Substances 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
201000005202 lung cancer Diseases 0.000 description 1
208000020816 lung neoplasm Diseases 0.000 description 1
230000000527 lymphocytic effect Effects 0.000 description 1
201000000564 macroglobulinemia Diseases 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
230000014759 maintenance of location Effects 0.000 description 1
VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
230000003211 malignant effect Effects 0.000 description 1
208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
239000000594 mannitol Substances 0.000 description 1
235000010355 mannitol Nutrition 0.000 description 1
GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 description 1
229960001428 mercaptopurine Drugs 0.000 description 1
230000002503 metabolic effect Effects 0.000 description 1
229910052751 metal Inorganic materials 0.000 description 1
239000002184 metal Substances 0.000 description 1
229960000485 methotrexate Drugs 0.000 description 1
229920000609 methyl cellulose Polymers 0.000 description 1
239000001923 methylcellulose Substances 0.000 description 1
235000010981 methylcellulose Nutrition 0.000 description 1
229950009847 meturedepa Drugs 0.000 description 1
QTFKTBRIGWJQQL-UHFFFAOYSA-N meturedepa Chemical compound C1C(C)(C)N1P(=O)(NC(=O)OCC)N1CC1(C)C QTFKTBRIGWJQQL-UHFFFAOYSA-N 0.000 description 1
229960004857 mitomycin Drugs 0.000 description 1
229960000350 mitotane Drugs 0.000 description 1
229960001156 mitoxantrone Drugs 0.000 description 1
KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 description 1
238000002156 mixing Methods 0.000 description 1
239000004570 mortar (masonry) Substances 0.000 description 1
229930014626 natural product Natural products 0.000 description 1
239000006199 nebulizer Substances 0.000 description 1
230000014399 negative regulation of angiogenesis Effects 0.000 description 1
229910052757 nitrogen Inorganic materials 0.000 description 1
239000003960 organic solvent Substances 0.000 description 1
239000003791 organic solvent mixture Substances 0.000 description 1
201000008968 osteosarcoma Diseases 0.000 description 1
229940045681 other alkylating agent in atc Drugs 0.000 description 1
229940127075 other antimetabolite Drugs 0.000 description 1
229960001592 paclitaxel Drugs 0.000 description 1
201000002528 pancreatic cancer Diseases 0.000 description 1
208000008443 pancreatic carcinoma Diseases 0.000 description 1
230000000737 periodic effect Effects 0.000 description 1
239000012071 phase Substances 0.000 description 1
239000002504 physiological saline solution Substances 0.000 description 1
239000000049 pigment Substances 0.000 description 1
239000006187 pill Substances 0.000 description 1
NUKCGLDCWQXYOQ-UHFFFAOYSA-N piposulfan Chemical compound CS(=O)(=O)OCCC(=O)N1CCN(C(=O)CCOS(C)(=O)=O)CC1 NUKCGLDCWQXYOQ-UHFFFAOYSA-N 0.000 description 1
229950001100 piposulfan Drugs 0.000 description 1
239000004014 plasticizer Substances 0.000 description 1
229910052697 platinum Inorganic materials 0.000 description 1
229920000642 polymer Polymers 0.000 description 1
229920001592 potato starch Polymers 0.000 description 1
229940116317 potato starch Drugs 0.000 description 1
230000001376 precipitating effect Effects 0.000 description 1
229960004694 prednimustine Drugs 0.000 description 1
XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 1
229960004618 prednisone Drugs 0.000 description 1
239000000955 prescription drug Substances 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
230000002335 preservative effect Effects 0.000 description 1
CPTBDICYNRMXFX-UHFFFAOYSA-N procarbazine Chemical compound CNNCC1=CC=C(C(=O)NC(C)C)C=C1 CPTBDICYNRMXFX-UHFFFAOYSA-N 0.000 description 1
229960000624 procarbazine Drugs 0.000 description 1
239000000583 progesterone congener Substances 0.000 description 1
239000003380 propellant Substances 0.000 description 1
WOLQREOUPKZMEX-UHFFFAOYSA-N pteroyltriglutamic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(=O)NC(CCC(=O)NC(CCC(O)=O)C(O)=O)C(O)=O)C(O)=O)C=C1 WOLQREOUPKZMEX-UHFFFAOYSA-N 0.000 description 1
150000003212 purines Chemical class 0.000 description 1
150000003230 pyrimidines Chemical class 0.000 description 1
102000005962 receptors Human genes 0.000 description 1
108020003175 receptors Proteins 0.000 description 1
230000033458 reproduction Effects 0.000 description 1
229940100486 rice starch Drugs 0.000 description 1
239000012047 saturated solution Substances 0.000 description 1
238000012216 screening Methods 0.000 description 1
239000008159 sesame oil Substances 0.000 description 1
235000011803 sesame oil Nutrition 0.000 description 1
201000000849 skin cancer Diseases 0.000 description 1
150000003384 small molecules Chemical class 0.000 description 1
235000010413 sodium alginate Nutrition 0.000 description 1
239000000661 sodium alginate Substances 0.000 description 1
229940005550 sodium alginate Drugs 0.000 description 1
239000007901 soft capsule Substances 0.000 description 1
239000012439 solid excipient Substances 0.000 description 1
230000003595 spectral effect Effects 0.000 description 1
239000007921 spray Substances 0.000 description 1
238000013112 stability test Methods 0.000 description 1
201000011549 stomach cancer Diseases 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
239000000829 suppository Substances 0.000 description 1
239000002511 suppository base Substances 0.000 description 1
230000004083 survival effect Effects 0.000 description 1
239000000375 suspending agent Substances 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
239000006188 syrup Substances 0.000 description 1
235000020357 syrup Nutrition 0.000 description 1
229960001603 tamoxifen Drugs 0.000 description 1
239000011975 tartaric acid Substances 0.000 description 1
RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
229960004964 temozolomide Drugs 0.000 description 1
NRUKOCRGYNPUPR-QBPJDGROSA-N teniposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@@H](OC[C@H]4O3)C=3SC=CC=3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 NRUKOCRGYNPUPR-QBPJDGROSA-N 0.000 description 1
229960001278 teniposide Drugs 0.000 description 1
229960001712 testosterone propionate Drugs 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
238000002076 thermal analysis method Methods 0.000 description 1
125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 description 1
229960003087 tioguanine Drugs 0.000 description 1
239000004408 titanium dioxide Substances 0.000 description 1
238000012546 transfer Methods 0.000 description 1
IUCJMVBFZDHPDX-UHFFFAOYSA-N tretamine Chemical compound C1CN1C1=NC(N2CC2)=NC(N2CC2)=N1 IUCJMVBFZDHPDX-UHFFFAOYSA-N 0.000 description 1
229950001353 tretamine Drugs 0.000 description 1
150000003626 triacylglycerols Chemical class 0.000 description 1
150000003918 triazines Chemical class 0.000 description 1
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
CYRMSUTZVYGINF-UHFFFAOYSA-N trichlorofluoromethane Chemical compound FC(Cl)(Cl)Cl CYRMSUTZVYGINF-UHFFFAOYSA-N 0.000 description 1
229940029284 trichlorofluoromethane Drugs 0.000 description 1
OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
229960001055 uracil mustard Drugs 0.000 description 1
150000003672 ureas Chemical class 0.000 description 1
229950006929 uredepa Drugs 0.000 description 1
SPDZFJLQFWSJGA-UHFFFAOYSA-N uredepa Chemical compound C1CN1P(=O)(NC(=O)OCC)N1CC1 SPDZFJLQFWSJGA-UHFFFAOYSA-N 0.000 description 1
210000003932 urinary bladder Anatomy 0.000 description 1
201000005112 urinary bladder cancer Diseases 0.000 description 1
239000002966 varnish Substances 0.000 description 1
229960003048 vinblastine Drugs 0.000 description 1
JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 1
229960004528 vincristine Drugs 0.000 description 1
OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 1
OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
229960004355 vindesine Drugs 0.000 description 1
UGGWPQSBPIFKDZ-KOTLKJBCSA-N vindesine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(N)=O)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1N=C1[C]2C=CC=C1 UGGWPQSBPIFKDZ-KOTLKJBCSA-N 0.000 description 1
238000005406 washing Methods 0.000 description 1
229940100445 wheat starch Drugs 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
General Health & Medical Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Chemical Kinetics & Catalysis (AREA)
Diabetes (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Hematology (AREA)
Emergency Medicine (AREA)
Endocrinology (AREA)
Obesity (AREA)
Oncology (AREA)
Dermatology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Pyrrole Compounds (AREA)

NO20041054A 2001-08-15 2004-03-12 Krystaller som inneholder et eplesyresalt av N-[2-(dietylamino)etyl]-5-[(5-fluor- 2-okso-3H-indol-3-yliden)metyl]-2,4-dimetyl-1H-pyrrol-3-karboksamid, fremgangsmater for fremstilling av disse og preparater derav NO326508B1 (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US31235301P	2001-08-15	2001-08-15
PCT/US2002/025649 WO2003016305A1 (en)	2001-08-15	2002-08-13	Crystals including a malic acid salt of n-[2-(diethylamino) ethyl]-5-[(5-fluoro-2-oxo-3h-indole-3-ylidene) methyl]-2, 4-dimethyl-1h-pyrrole-3-carboxamide, processes for its preparation and compositions thereof

Publications (2)

Publication Number	Publication Date
NO20041054L NO20041054L (no)	2004-03-12
NO326508B1 true NO326508B1 (no)	2008-12-15

Family

ID=23211067

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20041054A NO326508B1 (no)	2001-08-15	2004-03-12	Krystaller som inneholder et eplesyresalt av N-[2-(dietylamino)etyl]-5-[(5-fluor- 2-okso-3H-indol-3-yliden)metyl]-2,4-dimetyl-1H-pyrrol-3-karboksamid, fremgangsmater for fremstilling av disse og preparater derav

Country Status (43)

Country	Link
US (2)	US20030069298A1 (es)
EP (3)	EP2332934B1 (es)
JP (1)	JP4159988B2 (es)
KR (1)	KR100639281B1 (es)
CN (2)	CN100439360C (es)
AP (1)	AP1660A (es)
AR (1)	AR036261A1 (es)
AU (1)	AU2002324684B2 (es)
BG (1)	BG108553A (es)
BR (1)	BR0211612A (es)
CA (1)	CA2455050C (es)
CO (1)	CO5550431A2 (es)
CU (1)	CU23713B7 (es)
CY (1)	CY1121552T1 (es)
CZ (1)	CZ2004196A3 (es)
DK (2)	DK3168218T3 (es)
EA (1)	EA006445B9 (es)
EC (1)	ECSP044975A (es)
ES (3)	ES2453164T3 (es)
GE (1)	GEP20063777B (es)
HK (2)	HK1066542A1 (es)
HR (1)	HRP20040112B1 (es)
HU (1)	HU229206B1 (es)
IL (1)	IL160097A0 (es)
IS (1)	IS7147A (es)
MA (1)	MA27058A1 (es)
ME (1)	ME00414B (es)
MX (1)	MXPA04001452A (es)
MY (1)	MY139383A (es)
NO (1)	NO326508B1 (es)
NZ (1)	NZ531232A (es)
OA (1)	OA12650A (es)
PL (1)	PL216524B1 (es)
PT (2)	PT3168218T (es)
RS (1)	RS53251B (es)
SI (2)	SI3168218T1 (es)
SK (1)	SK902004A3 (es)
TN (1)	TNSN04028A1 (es)
TR (1)	TR201900509T4 (es)
TW (1)	TWI269796B (es)
UA (1)	UA76483C2 (es)
WO (1)	WO2003016305A1 (es)
ZA (1)	ZA200400706B (es)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2455050C (en)	2001-08-15	2007-02-20	Pharmacia & Upjohn Company	Crystals including a malic acid salt of n-[2-(diethylamino) ethyl]-5-[(5-fluoro-2-oxo-3h-indole-3-ylidene) methyl]-2, 4-dimethyl-1h-pyrrole-3-carboxamide, processes for its preparation and compositions thereof
HN2003000272A (es) *	2002-09-10	2008-07-29	Pharmacia Italia Spa	Formulaciones que comprenden un compuesto de indolinona
ES2348623T3 (es) *	2003-10-02	2010-12-09	PHARMACIA & UPJOHN COMPANY LLC	Sales y polimorfos de un compuesto de indolinona sustituidos con pirrol.
US20060009510A1 (en) *	2004-07-09	2006-01-12	Pharmacia & Upjohn Company Llc	Method of synthesizing indolinone compounds
DK1773811T3 (da) *	2004-07-22	2010-12-13	Lilly Co Eli	Krystallinsk variabelt hydrat af (s)-6-(4-(2-((3-(9h-carbazol-4-yloxy)-2-hydroxypropyl)amin)-2-methylpropyl)phenoxy)-3-pyridincarboxamid-hemisuccinatsalt
CA2603445A1 (en) *	2005-05-12	2006-11-16	Pfizer Inc.	Anticancer combination therapy using sunitinib malate
NZ566033A (en) *	2005-09-19	2011-04-29	Pfizer Prod Inc	Solid salt forms of a pyrrole substituted 2-indolinone
US20090004213A1 (en)	2007-03-26	2009-01-01	Immatics Biotechnologies Gmbh	Combination therapy using active immunotherapy
EP2253629A1 (en)	2007-11-21	2010-11-24	Teva Pharmaceutical Industries Ltd.	Polymorphs of racemic sunitinib malate, compositions containing them and preparation thereof
US20100256392A1 (en) *	2007-11-21	2010-10-07	Teva Pharmaceutical Industries Ltd.	Polymorphs of sunitinib base and processes for preparation thereof
EP2229380A1 (en) *	2007-12-12	2010-09-22	Medichem, S.A.	Polymorphic forms of a 3-pyrrole substituted 2-indolinone
EP2113248A1 (en)	2008-04-29	2009-11-04	Ratiopharm GmbH	Pharmaceutical composition comprising N-[2-(diethylamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2-,4-dimethyl-1H-pyrrole-3-carboxamide
EP2090306A1 (en)	2008-02-13	2009-08-19	Ratiopharm GmbH	Pharmaceutical compositions comprising N-[2-(diethylamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide
EP2252607A2 (en) *	2008-02-21	2010-11-24	Generics [UK] Limited	Novel polymorphs and processes for their preparation
EP2098521A1 (en) *	2008-03-06	2009-09-09	Ratiopharm GmbH	Crystal forms of N-[2-(diethylamino) ethyl]-5-[fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrolle-3-carboxamide and methods for their prepparation
EP2274303B1 (en) *	2008-03-31	2012-08-29	Teva Pharmaceutical Industries Ltd.	Processes for preparing sunitinib and salts thereof
CA2720943A1 (en)	2008-04-16	2009-10-22	Natco Pharma Limited	Novel polymorphic forms of sunitinib base
EP2292613B1 (en) *	2008-05-23	2015-09-30	Shanghai Institute of Pharmaceutical Industry	Dihydroindolinone derivatives
AR072117A1 (es) *	2008-06-13	2010-08-04	Medichem Sa	Procedimiento para preparar una sal de malato 3-pirrol sustituido 2-indolinona, intermediario de sintesis y una composicion farmaceutica que la comprende.
EP2138167A1 (en)	2008-06-24	2009-12-30	ratiopharm GmbH	Pharmaceutical composition comprising N-[2-(Diethylamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene) methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide
WO2009156837A2 (en) *	2008-06-26	2009-12-30	Medichem, S.A.	Amorphous form of a 3-pyrrole substituted 2-indolinone malate salt
CN102203085A (zh) *	2008-07-10	2011-09-28	基因里克斯(英国)有限公司	用于制备苹果酸舒尼替尼晶体形式的新方法
CN102164913A (zh) *	2008-07-24	2011-08-24	麦迪凯姆股份公司	一种3-吡咯替代的2-吲哚酮苹果酸盐的结晶体形式
CA2731605A1 (en) *	2008-07-24	2010-01-28	Teva Pharmaceutical Industries Ltd.	Sunitinib and salts thereof and their polymorphs
JP2012500838A (ja) *	2008-08-25	2012-01-12	ジェネリクス・（ユーケー）・リミテッド	スニチニブの新規な多形およびその調製方法
AU2009286520A1 (en) *	2008-08-25	2010-03-04	Generics [Uk] Limited	Crystalline form of sunitinib and processes for its preparation
WO2010041134A1 (en) *	2008-10-10	2010-04-15	Medichem, S.A.	Process for preparing a 3-pyrrole subsituted 2-indolinone malate salt
EP2181991A1 (en) *	2008-10-28	2010-05-05	LEK Pharmaceuticals D.D.	Novel salts of sunitinib
EP2186809A1 (en) *	2008-11-13	2010-05-19	LEK Pharmaceuticals D.D.	New crystal form of sunitinib malate
EP2896618A1 (en)	2009-01-02	2015-07-22	Hetero Research Foundation	Polymorphs of sunitinib malate
TW202241853A (zh)	2009-01-16	2022-11-01	美商艾克塞里克斯公司	包含n-(4-{[6,7-雙(甲氧基)喹啉-4-基]氧基}苯基)-n'-(4-氟苯基)環丙烷-1,1-二甲醯胺之蘋果酸鹽之醫藥組合物及其用途
EP2255792A1 (en)	2009-05-20	2010-12-01	Ratiopharm GmbH	Pharmaceutical compositions for N-[2-(Diethylamino)ethyl]5-[(fluoro-1,2-dihydro-2-oxo-3H-indole-3-ylidene) methyl]-2,4-dimenthyl-1H-pyrrole-3-carboxamide
WO2011004200A1 (en)	2009-07-10	2011-01-13	Generics [Uk] Limited	Novel pyrrole derivatives
AU2010296849A1 (en)	2009-09-16	2012-05-03	Ranbaxy Laboratories Limited	Salts of sunitinib
EP2499133A2 (en)	2009-11-12	2012-09-19	Ranbaxy Laboratories Limited	Process for the preparation of crystalline form i of l-malic acid salt of sunitinib
EP2501694A1 (en)	2009-11-19	2012-09-26	Ranbaxy Laboratories Limited	Process for the preparation of crystalline form ii of l-malic acid salt of sunitinib
WO2011092664A1 (en)	2010-01-29	2011-08-04	Ranbaxy Laboratories Limited	Crystalline forms of l-malic acid salt of sunitinib
WO2011100325A2 (en)	2010-02-09	2011-08-18	Sicor Inc.	Polymorphs of sunitinib salts
WO2011104555A2 (en)	2010-02-25	2011-09-01	Generics [Uk] Limited	Novel process
EP2542550A1 (en)	2010-03-04	2013-01-09	Ranbaxy Laboratories Limited	Process for the direct preparation of malic acid salt of sunitinib
US20160185760A1 (en)	2010-03-18	2016-06-30	Ranbaxy Laboratories Limited	Process for the preparation of malic acid salt of sunitinib
WO2011128699A2 (en)	2010-04-16	2011-10-20	Generics [Uk] Limited	Novel process
WO2012042421A1 (en)	2010-09-29	2012-04-05	Pfizer Inc.	Method of treating abnormal cell growth
EP2699598B1 (en)	2011-04-19	2019-03-06	Pfizer Inc	Combinations of anti-4-1bb antibodies and adcc-inducing antibodies for the treatment of cancer
ES2709110T3 (es)	2012-03-23	2019-04-15	Laurus Labs Ltd	Un proceso mejorado para la preparación de sunitinib y sus sales de adición de ácido
PL399027A1 (pl)	2012-04-27	2013-10-28	Instytut Farmaceutyczny	Sposób otrzymywania N-[2-(dietylamino)etylo]-5-formylo-2,4-dimetylo-1H-pirolo-3-karboksyamidu o wysokiej czystosci i jego zastosowanie do wytwarzania sunitynibu
EP2844282B1 (en)	2012-05-04	2019-06-12	Pfizer Inc	Prostate-associated antigens and vaccine-based immunotherapy regimens
US9278955B2 (en)	2013-10-18	2016-03-08	Sun Pharmaceutical Industries Limited	Ascorbic acid salt of sunitinib
US9604968B2 (en) *	2013-10-18	2017-03-28	Sun Pharmaceutical Industries Limited	Pure crystalline Form II of L-malic acid salt of sunitinib and processes for its preparation
KR102006527B1 (ko)	2013-11-01	2019-08-02	화이자 인코포레이티드	전립선-연관 항원의 발현을 위한 벡터
CN104693187A (zh) *	2013-12-10	2015-06-10	安杰世纪生物科技（北京）有限公司	一种舒尼替尼L-苹果酸盐晶型λ及其制备方法
CN104744442B (zh) *	2013-12-25	2019-05-28	江苏豪森药业集团有限公司	苹果酸舒尼替尼的制备方法
RU2567535C1 (ru) *	2014-10-01	2015-11-10	Олег Ростиславович Михайлов	КРИСТАЛЛИЧЕСКАЯ ε-МОДИФИКАЦИЯ N-[2-(ДИЭТИЛАМИНО)ЭТИЛ]-5-[(Z)-(5-ФТОР-1,2-ДИГИДРО-2-ОКСО-3Н-ИНДОЛ-3-ИЛИДЕН)МЕТИЛ]-2,4-ДИМЕТИЛ-1Н-ПИРРОЛ-3-КАРБОКСАМИД МАЛАТА, СПОСОБ ЕЕ ПОЛУЧЕНИЯ И ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ НА ЕЕ ОСНОВЕ
CN105712979A (zh) *	2014-12-05	2016-06-29	广州白云山医药集团股份有限公司白云山制药总厂	一种苹果酸舒尼替尼晶型ⅰ的制备方法
EP3539536A1 (en)	2018-03-15	2019-09-18	MH10 Spolka z ograniczona odpowiedzialnoscia	A pharmaceutical composition of sunitinib or its salt thereof in its polymorphic form i
WO2020216450A1 (en)	2019-04-25	2020-10-29	Synthon B.V.	Pharmaceutical composition comprising amorphous sunitinib
JP2022529290A (ja) *	2019-04-18	2022-06-20	メーターヘルスインコーポレイテッド	呼吸性不整脈を処置するための方法および組成物
KR20240025990A (ko)	2022-08-19	2024-02-27	주식회사 스카이테라퓨틱스	무정형 수니티닙, 그 제조방법 및 이를 포함한 의약 조성물

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE10299004I2 (de)	1990-10-15	2006-03-16	Pfizer	Indolderivate
IL100091A (en) *	1990-12-12	1998-08-16	Zeneca Ltd	Pharmaceutical preparations containing the physical form of [4] 5) Cyclopentyloxycarbyl (amino 1 methyl indole 3 methyl methyl [3 methoxybenzoyl [2 methylbenzole)
KR100286411B1 (ko)	1992-06-05	2001-04-16	더블유. 지. 콜	치환된 트리아졸의 설페이트 염, 이의 제조방법 및 이를 포함하는 약제학적 조성물
CA2155322C (en)	1993-03-12	2000-02-29	Michael J. Dunn	Crystalline ceftiofur free acid
US6329364B1 (en)	1994-08-31	2001-12-11	Eli Lilly And Company	Crystalline form of dihydro-2,3-benzodiazepine derivative
DE19503966C2 (de)	1995-02-07	1998-07-02	Mack Chem Pharm	Kristallmodifikation von 2,4-Diamino-6-hydroxymethylpteridin-Hydrobromid, Verfahren zu dessen Herstellung und dessen Verwendung
US5597663A (en) *	1995-05-30	1997-01-28	Motorola, Inc.	Low temperature molten lithium salt electrolytes for electrochemical cells
US5880141A (en) *	1995-06-07	1999-03-09	Sugen, Inc.	Benzylidene-Z-indoline compounds for the treatment of disease
US5673451A (en) *	1995-07-06	1997-10-07	Moore; James R.	Instructional toothbrush
US20020038021A1 (en)	1995-12-11	2002-03-28	Barton Kathleen P.	Eplerenone crystalline form exhibiting enhanced dissolution rate
US20020045746A1 (en)	1995-12-11	2002-04-18	Barton Kathleen P.	Eplerenone crystalline form
US6066647A (en)	1996-07-29	2000-05-23	Pfizer Inc.	Zwitterionic forms of trovafloxacin
TR199900298T2 (xx) *	1996-08-14	1999-05-21	G.D. Searle &Co.	4-(5-Metil-3-fenilizoksazol-4-il) BenzenS�lfonamidin kristal halinde bi�imi.
CN1104378C (zh)	1996-12-25	2003-04-02	日本化药株式会社	顺铂细粉及其制备方法
US5777185A (en) *	1997-09-09	1998-07-07	Laroche Industries Inc.	Production of organic fluorine compounds
US6133305A (en) *	1997-09-26	2000-10-17	Sugen, Inc.	3-(substituted)-2-indolinones compounds and use thereof as inhibitors of protein kinase activity
US6012678A (en) *	1998-01-26	2000-01-11	The Boeing Company	Galley vacuum waste disposal system
PT1020454E (pt)	1998-06-19	2009-12-21	Teijin Pharma Ltd	Modificações polimórficas do ácido 2-(3-ciano-4-isobutiloxifenil)-4-metil-5-tiazole-carboxílico e processos para a sua preparação
JP2002532492A (ja) *	1998-12-17	2002-10-02	エフ．ホフマン−ラロシュアーゲー	サイクリン−依存性キナーゼ、特にｃｄｋ２のインヒビターとしての４−アルケニル（及びアルキニル）オキシドール
US6239141B1 (en)	1999-06-04	2001-05-29	Pfizer Inc.	Trovafloxacin oral suspensions
ES2367007T3 (es) *	1999-11-24	2011-10-27	Sugen, Inc.	Derivados de indolinona ionizables y su uso como ligandos de ptk.
NZ520640A (en) *	2000-02-15	2005-04-29	Upjohn Co	Pyrrole substituted 2-indolinone protein kinase inhibitors
US6316672B1 (en)	2001-01-31	2001-11-13	Grayson Walker Stowell	Form a of fluoxetine hydrochloride
CA2455050C (en)	2001-08-15	2007-02-20	Pharmacia & Upjohn Company	Crystals including a malic acid salt of n-[2-(diethylamino) ethyl]-5-[(5-fluoro-2-oxo-3h-indole-3-ylidene) methyl]-2, 4-dimethyl-1h-pyrrole-3-carboxamide, processes for its preparation and compositions thereof
EP2252607A2 (en)	2008-02-21	2010-11-24	Generics [UK] Limited	Novel polymorphs and processes for their preparation
WO2009156837A2 (en)	2008-06-26	2009-12-30	Medichem, S.A.	Amorphous form of a 3-pyrrole substituted 2-indolinone malate salt

2002
- 2002-08-13 CA CA002455050A patent/CA2455050C/en not_active Expired - Lifetime
- 2002-08-13 HU HU0700036A patent/HU229206B1/hu unknown
- 2002-08-13 AU AU2002324684A patent/AU2002324684B2/en not_active Expired
- 2002-08-13 OA OA1200400044A patent/OA12650A/en unknown
- 2002-08-13 ES ES02759342.5T patent/ES2453164T3/es not_active Expired - Lifetime
- 2002-08-13 EP EP11156767.3A patent/EP2332934B1/en not_active Expired - Lifetime
- 2002-08-13 BR BR0211612-0A patent/BR0211612A/pt not_active Application Discontinuation
- 2002-08-13 ME MEP-2008-520A patent/ME00414B/me unknown
- 2002-08-13 ES ES11156767.3T patent/ES2623094T3/es not_active Expired - Lifetime
- 2002-08-13 GE GE5446A patent/GEP20063777B/en unknown
- 2002-08-13 UA UA2004021084A patent/UA76483C2/uk unknown
- 2002-08-13 EP EP02759342.5A patent/EP1419151B1/en not_active Expired - Lifetime
- 2002-08-13 IL IL16009702A patent/IL160097A0/xx active IP Right Grant
- 2002-08-13 SI SI200231093T patent/SI3168218T1/sl unknown
- 2002-08-13 DK DK16196036.4T patent/DK3168218T3/en active
- 2002-08-13 ES ES16196036T patent/ES2705063T3/es not_active Expired - Lifetime
- 2002-08-13 WO PCT/US2002/025649 patent/WO2003016305A1/en active IP Right Grant
- 2002-08-13 NZ NZ531232A patent/NZ531232A/en not_active IP Right Cessation
- 2002-08-13 CN CNB02815892XA patent/CN100439360C/zh not_active Expired - Lifetime
- 2002-08-13 US US10/218,985 patent/US20030069298A1/en not_active Abandoned
- 2002-08-13 CN CNB2005101286242A patent/CN100364991C/zh not_active Expired - Lifetime
- 2002-08-13 TR TR2019/00509T patent/TR201900509T4/tr unknown
- 2002-08-13 RS YU10304A patent/RS53251B/sr unknown
- 2002-08-13 SK SK90-2004A patent/SK902004A3/sk unknown
- 2002-08-13 PL PL368317A patent/PL216524B1/pl unknown
- 2002-08-13 DK DK02759342.5T patent/DK1419151T3/da active
- 2002-08-13 KR KR1020047002173A patent/KR100639281B1/ko active IP Right Grant
- 2002-08-13 AP APAP/P/2004/002976A patent/AP1660A/en active
- 2002-08-13 CZ CZ2004196A patent/CZ2004196A3/cs unknown
- 2002-08-13 EA EA200400183A patent/EA006445B9/ru unknown
- 2002-08-13 PT PT16196036T patent/PT3168218T/pt unknown
- 2002-08-13 MX MXPA04001452A patent/MXPA04001452A/es active IP Right Grant
- 2002-08-13 JP JP2003521228A patent/JP4159988B2/ja not_active Expired - Lifetime
- 2002-08-13 PT PT2759342T patent/PT1419151E/pt unknown
- 2002-08-13 SI SI200231043T patent/SI1419151T1/sl unknown
- 2002-08-13 EP EP16196036.4A patent/EP3168218B1/en not_active Expired - Lifetime
- 2002-08-15 TW TW091118419A patent/TWI269796B/zh active
- 2002-08-15 AR ARP020103088A patent/AR036261A1/es unknown
- 2002-08-15 MY MYPI20023032A patent/MY139383A/en unknown
2004
- 2004-01-16 CO CO04002781A patent/CO5550431A2/es not_active Application Discontinuation
- 2004-01-28 ZA ZA2004/00706A patent/ZA200400706B/en unknown
- 2004-01-29 BG BG108553A patent/BG108553A/bg unknown
- 2004-02-02 HR HR20040112A patent/HRP20040112B1/xx not_active IP Right Cessation
- 2004-02-10 IS IS7147A patent/IS7147A/is unknown
- 2004-02-10 EC EC2004004975A patent/ECSP044975A/es unknown
- 2004-02-11 MA MA27522A patent/MA27058A1/fr unknown
- 2004-02-12 TN TNP2004000028A patent/TNSN04028A1/fr unknown
- 2004-02-12 CU CU20040029A patent/CU23713B7/es active IP Right Grant
- 2004-03-12 NO NO20041054A patent/NO326508B1/no not_active IP Right Cessation
- 2004-12-01 HK HK04109465.3A patent/HK1066542A1/xx not_active IP Right Cessation
2006
- 2006-07-28 HK HK06108404A patent/HK1088008A1/xx not_active IP Right Cessation
2007
- 2007-04-26 US US11/740,644 patent/US7435832B2/en not_active Expired - Lifetime
2018
- 2018-12-12 CY CY20181101336T patent/CY1121552T1/el unknown

Also Published As

Publication number	Publication date
ES2705063T3 (es)	2019-03-21
HK1088008A1 (en)	2006-10-27
EA006445B1 (ru)	2005-12-29
MXPA04001452A (es)	2004-05-20
GEP20063777B (en)	2006-03-27
EA200400183A1 (ru)	2004-08-26
CN1789264A (zh)	2006-06-21
CY1121552T1 (el)	2020-05-29
NZ531232A (en)	2004-11-26
KR100639281B1 (ko)	2006-10-31
CN1543462A (zh)	2004-11-03
SK902004A3 (sk)	2005-03-04
EP3168218B1 (en)	2018-11-14
EP3168218A1 (en)	2017-05-17
HK1066542A1 (en)	2005-03-24
JP4159988B2 (ja)	2008-10-01
TR201900509T4 (tr)	2019-02-21
CU20040029A7 (es)	2008-03-14
IL160097A0 (en)	2004-06-20
CZ2004196A3 (cs)	2005-01-12
KR20040030074A (ko)	2004-04-08
HU229206B1 (en)	2013-09-30
EP1419151B1 (en)	2014-02-26
MY139383A (en)	2009-09-30
US20070191458A1 (en)	2007-08-16
WO2003016305A1 (en)	2003-02-27
BG108553A (bg)	2005-04-30
SI3168218T1 (sl)	2019-05-31
JP2005503386A (ja)	2005-02-03
AP2004002976A0 (en)	2004-03-31
OA12650A (en)	2006-06-19
NO20041054L (no)	2004-03-12
PT1419151E (pt)	2014-03-27
PL368317A1 (en)	2005-03-21
US7435832B2 (en)	2008-10-14
IS7147A (is)	2004-02-10
ZA200400706B (en)	2005-05-25
US20030069298A1 (en)	2003-04-10
AU2002324684B2 (en)	2006-10-05
AP1660A (en)	2006-09-09
EP2332934A1 (en)	2011-06-15
CN100439360C (zh)	2008-12-03
AR036261A1 (es)	2004-08-25
ECSP044975A (es)	2004-03-23
EA006445B9 (ru)	2017-02-28
HUP0700036A2 (en)	2008-10-28
ES2623094T3 (es)	2017-07-10
DK3168218T3 (en)	2019-01-14
DK1419151T3 (da)	2014-03-31
CN100364991C (zh)	2008-01-30
MA27058A1 (fr)	2004-12-20
TNSN04028A1 (fr)	2006-06-01
TWI269796B (en)	2007-01-01
CO5550431A2 (es)	2005-08-31
CU23713B7 (es)	2011-10-05
PL216524B1 (pl)	2014-04-30
HRP20040112A2 (en)	2004-06-30
EP1419151A1 (en)	2004-05-19
ES2453164T3 (es)	2014-04-04
BR0211612A (pt)	2004-08-24
EP2332934B1 (en)	2017-03-01
SI1419151T1 (sl)	2014-04-30
CA2455050C (en)	2007-02-20
RS53251B (sr)	2014-08-29
ME00414B (me)	2011-10-10
CA2455050A1 (en)	2003-02-27
UA76483C2 (en)	2006-08-15
PT3168218T (pt)	2019-01-11
HRP20040112B1 (en)	2012-03-31
RS10304A (en)	2007-02-05

Legal Events

Date	Code	Title	Description
2022-09-12	MK1K	Patent expired

Publication	Publication Date	Title
NO326508B1 (no)	2008-12-15	Krystaller som inneholder et eplesyresalt av N-[2-(dietylamino)etyl]-5-[(5-fluor- 2-okso-3H-indol-3-yliden)metyl]-2,4-dimetyl-1H-pyrrol-3-karboksamid, fremgangsmater for fremstilling av disse og preparater derav
AU2002324684A1 (en)	2003-05-29	Crystals including a malic acid salt of N-[2-(diethylamino) ethyl]-5-[(5-fluoro-2-oxo-3H-indole-3-ylidene) methyl]-2, 4-dimethyl-1H-pyrrole-3-carboxamide, processes for its preparation and compositions thereof
TW200838512A (en)	2008-10-01	Crystalline forms of a thiazolidinedione compound and manufacturing methods thereof
CN104470920A (zh)	2015-03-25	固态形式的维罗菲尼胆碱盐
ZA200506370B (en)	2006-12-27	Polymorphs of pyrrole substituted 2-indolinone protein kinase inhibitors
WO2012122921A1 (zh)	2012-09-20	一种酪氨酸激酶抑制剂的盐形式
US20120142749A1 (en)	2012-06-07	Solid salt forms of a pyrrole substituted 2-indolinone
RU2684278C1 (ru)	2019-04-05	Фумарат пиридиламина и его кристаллы
TW201211036A (en)	2012-03-16	Useful salts of indazole derivative
JP2020520384A (ja)	2020-07-09	化合物の塩及びその結晶形態